NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Cancer (UK). Addendum to Haematological Cancers: improving outcomes (update). London: National Institute for Health and Care Excellence (NICE); 2016 May.
F.1. Members of the Guideline Committee
| GC Chair | |
|---|---|
| Dr Fergus Macbeth | Clinical adviser, Wales Cancer Trials Unit, Cardiff University |
| GC Lead Clinician | |
| Professor John Snowden | Consultant Haematologist and Director of Blood and Marrow Transplantation. Sheffield Teaching Hospitals NHS Foundation Trust |
| Group Members | |
| Dr Clare Rowntree | Consultant Haematologist, Cardiff and Vale University Health Board |
| Dr Christopher Dalley | Consultant Haematologist, Brighton and Sussex University Hospital Trust |
| Dr Deepak Mannari | Consultant Haematologist, Musgrove Park Hospital, Taunton |
| Dr Geoff Shenton | Consultant & Associate Clinical Lecturer in Paediatric and Adolescent Haematology & BMT, Great North Children's Hospital, Newcastle upon Tyne |
| Dr Elizabeth Soilleux | Consultant Haematopathologist, Oxford University Hospital NHS Trust and honorary senior clinical lecturer, Oxford University |
| Dr Andrew Jack | Consultant Haematopathologist, Leeds Cancer Centre |
| Mrs Sarah Steele | Senior Quality Improvement Lead, East of England Strategic Network |
| Dr Bhuey Sharma | Consultant Radiologist, The Royal Marsden Hospital NHS Foundation Trust, Department of Diagnostic Imaging, Surrey |
| Dr Christopher McNamara | Consultant Haematologist, The Royal Free London NHS Foundation Trust |
| Dr Mike Scott | Consultant Clinical Scientist and Clinical Lead, Cambridge University Hospital NHS Trust |
| Dr Nia Evans | Lead Haematology Pharmacist, Cardiff & Vale University Health Board |
| Ms Barbara von Barsewisch | Macmillan Lymphoma and CLL Clinical Nurse Specialist |
| Ms Marie Waller | Trainee Advanced Nurse Practitioner, Manchester Royal Infirmary |
| John Reeve | Patient and Carer Member |
| Alan Chant | Patient and Carer Member |
| Jonathan Pearce | Patient and Carer Member |
F.2. Declarations of interest
| Name | Interest declared | Type of interest | Decision taken |
|---|---|---|---|
| Fergus Macbeth | Chief investigator of a CRUK funded trial supported by Pfizer with free drug and unrestricted educational grant. | Non-personal financial non specific | Declare and participate in discussions on all topics as lung cancer is not being covered by the guideline. |
| Fergus Macbeth | Received reimbursement of travel and subsistence expenses for attending the World lung cancer conference. | Personal financial non-specific | Declare and participate in discussions on all topics as lung cancer is not being covered by the guideline. |
| John Snowden | Received an honorarium from MSD for chairing a meeting on antifungal drugs. | Personal financial Specific | Declare and must withdraw from topics which include antifungal drugs as an intervention until October 2014 |
| John Snowden | Received an honorarium from Celgene for chairing a meeting on myeloma drugs. | Personal financial Specific | Declare and participate in discussions on all topics as myeloma drugs are not being covered by the guideline. |
| John Snowden | Received an honorarium from MSD for attending an advisory board on Posoconazole | Personal financial Specific | Declare and participate in discussions on all topics as Posoconazole is not being covered by the guideline. |
| John Snowden | Received reimbursement of accommodation, travel, subsistence and registration fee from MSD, to attend the American Society for Hematology conference in New Orleans | Personal financial Non-specific | Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts. |
| John Snowden | Co-applicant on a research grant from Pfizer to investigate characterisation of central brain processing of chemotherapy-induced peripheral neuropathy | Non-personal financial Specific | Declare and participate in discussions on all topics as characterisation of central brain processing of chemotherapy-induced peripheral neuropathy is not being covered by the guideline. |
| John Snowden | Local principal investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC | Non-personal financial Specific | Declare and participate in discussions on all topics as no Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide is not being covered by the guideline. |
| John Snowden | Local principal investigator for the RIC UCBT trial (Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimen). Funded by The Sue Harris Bone Marrow Trust. | Non-personal financial Non-specific | Declare and participate in discussion of all topics as transplantation of umbilical cord blood is not being investigated by the guideline and has no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the MAC UCBT trial (Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen). Funded by The Sue Harris Bone Marrow Trust. | Non-personal financial Non-specific | Declare and participate in discussion of all topics as transplantation of umbilical cord blood is not being investigated by the guideline and has no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the LenaRIC trial (Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma). Funded by CTAAC. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the ProT-4 trial (Phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers). Funded by Leukaemia and Lymphoma Research. | Non-personal financial Non-specific | Declare and participate in discussion of all topics as transfer of lymphocytes after transplantation is not being investigated by the guideline and has no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the Myeloma IX trial (A randomised trial comparing second generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy). Funded by MRC | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials |
| John Snowden | Local principal investigator for the Myeloma X relapse (intensive) trial (to determine whether a high-dose procedure with autologous transplant is superior to low-dose consolidation therapy following re-induction chemotherapy in patients with relapsed myeloma). Funded by CRUK | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the RICAZA trial (Phase II study of the tolerability of adjunctive azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for acute myeloid leukaemia). Funded by Celgene. | Non-personal financial Non-specific | Declare and participate in discussion of all topics as transplantation for acute myeloid leukaemia is not being investigated by the guideline and has no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the Living with advanced relapsed myeloma study (cross sectional observational study to identify preventable and manageable late effects). Funded by Myeloma UK. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for a Phase 2, Multi-centre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma related Bone Disease. Funded by Janssen-Cilag Ltd. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the UK Haplo Trial (A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies). Funded by Leukaemia Lymphoma Research. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the UK Haplo Trial (A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies). Funded by Leukaemia Lymphoma Research. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Local principal investigator for the HLA Epitope trial (HLA epitope matched platelet transfusion in aplastic anaemia, MDS and AML patients) Funded by NHS Blood and Transplant (NHSBT) | Non-personal financial Non-specific | Declare and participate in discussions on all topics as aplastic anaemia, myelodysplastic syndrome and acute myeloid leukaemia are not being investigated by the guideline and no supervisory responsibility on trials. |
| John Snowden | Principal investigator of a charitable grant from Royal Hallamshire Hospital Leukaemia and Research Fund, for a bolt-on study to Myeloma X, relating to supportive care in myeloma. | Non-personal financial Specific | Declare and can participate in discussion of all topics as research not funded by the healthcare industry. |
| John Snowden | Co-investigator on the MUK5 trial (A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma). Funded by Myeloma UK | Non-personal financial Non-specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Co-investigator on the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Co-investigator on the AML 17 trial (Working parties on leukaemia in adults and children trial in AML or high risk MDS 17). Funded by CRUK | Non-personal financial Non-specific | Declare and participate in discussions on all topics as leukaemia, AML and MDS are not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the FiTT study (Investigating the effectiveness of co-morbidity assessment in male patients with myeloma and prostate cancer). Funded by Weston Park Hospital Cancer Charity and Sheffield Teaching Hospitals NHS Foundation trust. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Co-investigator on the AML 15 trial (Working parties on leukaemia in adults and children AML trial 15). Funded by MRC. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as leukaemia is not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the AML 16 trial (A programme of development for older patients with AML and high risk MDS). Funded by CRUK | Non-personal financial Non-specific | Declare and participate in discussions on all topics as AML and MDS are not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the MCL MiniAllo trial (Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma). Funded by CRUK, Genzyme Therapeutics, National Institute for Health Research Cancer Network (NRCN). | Non-personal financial Non-specific | Declare and participate in discussions on all topics as mantle cell lymphoma is not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the ORCHARRD trial (Ofatumumab rituximab chemoimmunotherapy ASCT relapsed refractory DLBCL). Funded by GlaxoSmithKline. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as diffuse large B cell lymphoma is not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the FIGARO trial (A randomised trial of the FLAMSA-BU conditioning regimen in patients with AML and MDS undergoing allogeneic stem cell transplantation). Funded by Leukaemia and Lymphoma Research. | Non-personal financial Non-specific | Declare and participate in discussions on all topics as AML and MDS are not being investigated by the guideline no supervisory responsibility on trial. |
| John Snowden | Co-investigator on the MUK 4 trial (phase II trial of combination treatment with Vorinostat, bortezomib and dexamethasone in patients with relapsed multiple myeloma). Funded by Myeloma UK | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Co-investigator on the SarCaBon trial (A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain). Funded by MRC | Non-personal financial Non-specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| John Snowden | Member of the UK Myeloma Forum. Involved in writing the evidence-based position statement: ‘The use of consolidation and maintenance treatment in myeloma’ | Personal non-financial | Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence and the guideline will not be investigating maintenance and consolidation therapy for myeloma. |
| John Snowden | Member of the UK Myeloma Forum has been involved in writing the evidence-based position statement: ‘The use of bendamustine in myeloma’ | Personal non-financial | Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence. |
| John Snowden | Executive member of the UK Myeloma Forum, a non-profit organisation for the support of UK health professionals and scientists in the myeloma field | Personal non-financial | Declare and participate in discussion on all topics as interest does not impact on content of the guideline. |
| John Snowden | Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene:Stradwick S, Freemantle N, Snowden J, Rodrigues F, Brereton N. 2012. Comparative Effectiveness of Lenalidomide plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. Blood (ASH Annual Meeting Abstracts); 120 (21): A4076 | Personal non-financial | Declare and participate in discussion on all topics as Comparative Effectiveness of Lenalidomide plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma is not being investigated by the guideline. |
| John Snowden | Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene: Stradwick S, Freemantle N, Vickers A, Rodrigues F, Monzini M, Brereton N, Snowden. 2013. Comparative Effectiveness of Lenalidomide Plus Dexamethasone Versus Bortezomib Subcutaneous for the Treatment of RRMM. Presented at the 14th International Myeloma Workshop (IMW); Kyoto, Japan; April 3–7. | Personal non-financial | Declare and participate in discussion on all topics as Comparative Effectiveness of Lenalidomide Plus Dexamethasone Versus Bortezomib Subcutaneous for the Treatment of RRMM is not being investigated by the guideline. |
| John Snowden | Received reimbursement of travel expenses from the organisers for speaking on quality in transplantation at the Joint Accreditation Committee in Autoimmune Diseases meeting | Personal financial Non-specific | Declare and participate in discussion on all guideline topics as expenses not beyond reasonable amounts. |
| John Snowden | Received an honorarium for from Sanofi for attending an advisory board on the mobilising agent plerixafor and possibly some future currently unlicensed drugs | Personal financial Non-specific | Declare and participate in discussion of all guideline topics as plerixafor is not being investigated by the guideline. |
| Clare Rowntree | Received an honorarium from Roche for attending an advisory board on GA101 in CLL. | Personal financial Non specific | Declare and participate in discussions on all topics as expenses not beyond a reasonable amount. |
| Clare Rowntree | Received an honorarium from Amgen for attending an advisory board on Blimatumomab in ALL | Personal financial Non specific | Declare and participate in discussions on all topics as expenses not beyond a reasonable amount. |
| Clare Rowntree | Received an honorarium from Amgen for giving a lecture on ALL in the elderly at the British Society for Haematology. | Personal financial Non specific | Declare and participate in discussions on all topics as expenses not beyond a reasonable amount. |
| Clare Rowntree | Local PI on MABCUTE trial (randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously). Funded by Roche. Trial is closed and in follow-up. No involvement in designing trial protocol. | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Clare Rowntree | Local PI on ECHELON-1 trial (A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma). Funded by Millenium Pharmaceuticals Ltd. No involvement in designing trial protocol | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Clare Rowntree | Member of the trial management group for the UKALL 14 (A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia). Funded by CTAAC. Involved in designing the trial protocol. | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Clare Rowntree | Member of the trial management group for the UKALL 2011 (United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011). Funded by Leukaemia & Lymphoma Research. Involved in designing the trial protocol. | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Clare Rowntree | Member of the trial management group for the UKALL 60+ (A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia). Funded by CRUK. Involved in designing the trial protocol | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Clare Rowntree | Member of the Teenage Cancer Trust advisory board. Advises on how to invest in research. | Personal Non-financial Specific | Chair persons action to declare and participate in discussions on all topics. |
| Christopher Dalley | Attending an advisory board organised by Novartis for Iron chelation therapy in low risk MDS | Personal financial Non-Specific | Declare and participate in discussion on all topics as Iron chelation therapy in low risk MDS is not being investigated by the guideline. |
| Christopher Dalley | Co-signatory for the departmental budget for training and education of department staff. Income is primarily from patient donations (but not Pharma) | Non-personal financial Non-specific | Declare and participate in discussion on all topics because not industry funded. |
| Christopher Dalley | Member of the BMT clinical reference group. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics. |
| Christopher Dalley | Member of the UK MDS executive. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics. |
| Christopher Dalley | Member of the UK NEQAS Executive for Leukocyte and immunophenotyping. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Christopher Dalley | Member of the MDS, NCRI group for clinical trials. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics. |
| Christopher Dalley | Was lead author on a published article for the Journal of Clinical Pathology on Specialist Integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. | Personal Non-financial Specific | Chair person's action to declare and participate in discussions on all topics. |
| Deepak Mannari | Received an honorarium from Celgene for chairing a meeting on the management of myeloma and myelodysplasia. | Personal financial Non specific | Declare and participate in discussion on all topics as management of myeloma and myelodysplasia is not being investigated by the guideline. |
| Deepak Mannari | Received an honorarium from Amgen for chairing a meeting on the management of immunothrobocytopenia. | Personal financial Non specific | Declare and participate in discussion on all topics as management of immunothrobocytopenia is not being investigated by the guideline. |
| Geoff Shenton | Principal investigator and member of the trial management group for MyeChild 01: Induction: daunoxome v mitoxantrone, Consolidation: Fludarabine/Cytarbine v high dose cyosine arabinoside, SCT conditioning. Funded by the University of Birmingham and the NCRI. | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Geoff Shenton | Principal Investigator and Co-investigator for the UK for the InteReALL Sr and HR trial for relapsed acute lymphoblastic leukaemia. Funded by the University of Birmingham and the NCRI. | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Geoff Shenton | Principal Investigator for Blinotunomab for relapsed leukaemia trial. Funded by Amgen. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Geoff Shenton | Member of the I=BFM resistant disease working party. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Geoff Shenton | Member of the UKCCSG (UK Children's Cancer Study Group now Children's Cancer and Leukaemia Group (CCLG) Bone Marrow Transplant Committee. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Geoff Shenton | Member of the Medical Research Council (MRC) Childhood Leukaemia Working Group (now CCLG Leukaemia Group) | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Geoff Shenton | Member of the Yorkshire and Humber Bone Marrow Transplant Executive | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Geoff Shenton | Member of the NCRI Paediatric Leukaemia CSG (ALL and AML subgroups) | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Andrew Jack | Member of a the trial management group for a Phase III randomised clinical trial comparing rituximab given every 14 days with CHOP given every 21 days (R-CHOP 14 vs21) for patients with newly diagnosed diffuse large B Cell non Hodgkins Lymphoma. Funded by Cancer Research UK and Chugai Pharma Europe Ltd. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator for a randomised evaluation of molecular targeted therapy with bortezomib in diffuse large B-cell lymphoma (REMoDL-B). Funded by Janssen-Cilag. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator for biomarker development and monoclonal antibodies for the treatment of lymphoma. Funded by Genentech Ltd. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator on a trial to compare remission rates of low grade non Hodgkin's lymphoma with GA101 vrs rituximab. Funded by Experimental Cancer Medicine (ECMC), Genentech Ltd, NCRN and Roche. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator on the stratification of treatment by molecular and genetic sub-typing for diffuse large B-cell lymphoma. Funded by Leukaemia and lymphoma research. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Represents the NCRI on the Lunenburg lymphoma biomarker consortium, the European and North American initiative for the development of biomarkers in clinical trials. | Personal Non-financial | Chair person's action to declare and participate in discussions on all topics as the interest is not specific to the content of the guideline. |
| Andrew Jack | Host Trust is contracted to provide diagnostic services for the GALLIUM trial to Roche. Responsible for supervising staff and ensuring the work is carried out to the required quality in line with the contract. | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no responsibility for the contract and does not provide any advice or opinion to Roche. |
| Andrew Jack | As head of department was involved in a joint project between Host trust, 14M Genomics and University of York to develop new diagnostics in genomics, ceased involvement when no longer head of department in October 2014. | Personal financial Non-Specific | Declare and participate in discussion on all topics as develop new diagnostics in genomics not being investigated by the guideline. |
| Andrew Jack | Received reimbursement of travelling and subsistence expenses from Roche for attending the American Society of Haematologists (ASH) meeting in December 2013. | Personal financial interest Specific | Declare and participate in discussions on all topics as expenses not beyond a reasonable amount |
| Andrew Jack | Member of a the trial management group for a Phase III randomised clinical trial comparing rituximab given every 14 days with CHOP given every 21 days (R-CHOP 14 vs21) for patients with newly diagnosed diffuse large B Cell non Hodgkins Lymphoma. Funded by Cancer Research UK and Chugai Pharma Europe Ltd. | Non-personal financial Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials |
| Andrew Jack | Principal investigator for a randomised evaluation of molecular targeted therapy with bortezomib in diffuse large B-cell lymphoma (REMoDL-B). Funded by Janssen-Cilag. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials |
| Andrew Jack | Principal investigator for biomarker development and monoclonal antibodies for the treatment of lymphoma. Funded by Genentech Ltd. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator on a trial to compare remission rates of low grade non Hodgkin's lymphoma with GA101 vrs rituximab. Funded by Experimental Cancer Medicine (ECMC), Genentech Ltd, NCRN and Roche. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Principal investigator on the stratification of treatment by molecular and genetic sub-typing for diffuse large B-cell lymphoma. Funded by Leukaemia and lymphoma research. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Andrew Jack | Represents the NCRI on the Lunenburg lymphoma biomarker consortium, the European and North American initiative for the development of biomarkers in clinical trials. | Personal non-financial interest Specific | Chair person's action to declare and participate in discussions on all topics as the interest is not specific to the content of the guideline. |
| Andrew Jack | Host Trust is contracted to provide diagnostic services for the GALLIUM trial to Roche. Responsible for supervising staff and ensuring the work is carried out to the required quality in line with the contract. | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no responsibility for the contract and does not provide any advice or opinion to Roche. |
| Andrew Jack | Has supervisory responsibility for a collaborative research project to identify targets for therapeutic antibody development. Funded by Genetech. | Non-personal financial Non-Specific | Declare and participate in discussions on all topics as therapeutic antibody development is not the focus of the guideline. |
| Sarah Steele | Volunteers as Treasurer for the Friends of West Suffolk Hospital. Responsible for keeping the books and part of the committee that decides how to spend the fund. Fund only used to support patients and staff of the hospital. | Non-personal financial Non-Specific | Chair person's action to declare and participate in discussions on all topics as the interest is not specific to the content of the guideline. |
| Bhuey Sharma | Received an honorarium from Roche Products Ltd for giving a lecture on “Metastatic breast cancer: future positive. Navigating the HER 2+ journey: Targeting and imaging invasion and metastases”. | Personal financial Non-specific | Declare and participate in discussions on all topics as breast cancer is not being investigated by the guideline. |
| Bhuey Sharma | Co-investigator on a multicentre randomised phase II study on CHEMO-T, Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell lymphoma. Funded by Royal Marsden NHS Foundation trust. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials |
| Bhuey Sharma | Co-investigator on a multicentre randomised phase II study on LEGEND comparing Lenalidonmide plus rituximab, gemcitabine, methylprednisolone and cisplatin (RG-EMP) in second line treatment of diffuse large B-cell lymphoma. Funded by Celgene Europe Ltd. | Non-personal financial interest Specific | Declare and participate in discussions on all topics as no supervisory responsibility on trials. |
| Christopher McNamara | Principal investigator for the GALLIUM trial on rituximab versus GA101 in combination with chemotherapy in first-line follicular and marginal zone lymphoma. Funded by NCR and Roche. Advised on setting up the laboratory diagnostics for patients participating in the trial, when the trial protocol was being determined | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has only provided advice on laboratory diagnostics components of the trial protocol. |
| Christopher McNamara | Local principal investigator for the PACIFICO trial (Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP (rituximab, cyclophosphamide, vincristine and prednisone) versus R-FC (rituximab, fludarabine and cyclophosphamide). Funded by CTAAC | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Christopher McNamara | Local principal investigator for the REMoDLB trial (A randomised evaluation to see whether adding bortezomib to standard combination chemotherapy and rituximab (RCHOP) can improve progression free survival in diffuse large B-cell lymphoma with Bortezomib). Funded by Janssen Cilag Ltd | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Christopher McNamara | Local principal investigator for the RATHL trial (a multicentre randomised phase II study to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin's lymphoma). Funded by CRUK | Non-personal financial Non-specific | Declare and participate in discussions on all topics as Hodgkin's lymphoma is not being covered by the guideline. |
| Christopher McNamara | Local principal investigator for the RAPID trial (A randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease). Funded by Leukaemia and Lymphoma Research | Non-personal financial Non-specific | Declare and participate in discussions on all topics as Hodgkin's lymphoma is not being covered by the guideline. |
| Christopher McNamara | Medical advisor to the Lymphoma Association | Personal non-financial | Declare and participate in discussions on all topics as interest is not specific to the content of the guideline. |
| Christopher McNamara | Local principal investigator for the REMoDLB trial (A randomised evaluation to see whether adding bortezomib to standard combination chemotherapy and rituximab (RCHOP) can improve progression free survival in diffuse large B-cell lymphoma with Bortezomib). Funded by Janssen Cilag Ltd | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Christopher McNamara | Local principal investigator for the RATHL trial (a multicentre randomised phase II study to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin's lymphoma). Funded by CRUK | Non-personal financial Non-specific | Declare and participate in discussion on all topics because not industry funded. |
| Christopher McNamara | Local principal investigator for the RAPID trial (A randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease). Funded by Leukaemia and Lymphoma Research | Non-personal financial Specific | Declare and participate in discussion on all topics because not industry funded. |
| Christopher McNamara | Principal investigator for the GALLIUM trial on rituximab versus GA101 in combination with chemotherapy in first-line follicular and marginal zone lymphoma. Funded by NCR and Roche. Advised on setting up the laboratory diagnostics for patients participating in the trial, when the trial protocol was being determined | Non-personal financial Specific | Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial. |
| Nia Evans | Member of British Oncology Pharmacists Association (BOPA) and UKBMT pharmacist's group | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Nia Evans | Lead pharmacist on a CRUK trial management group for AML18, and provides expert pharmacy input, responds to queries. Involved in checking the drug information and dosages were correct in the development of the trial protocol. | Non-personal financial Non-Specific | Declare and participate in discussion on all topics because not industry funded. |
| Nia Evans | Lead pharmacist and involved in developing the trial protocol for a CRUK trial management group for UKALL14. | Non-personal financial Non-Specific | Declare and participate in discussion on all topics because not industry funded. |
| Barbara von Barsewisch | Attending an advisory board organised by Roche on Subcutaneous administration of Mabtherea feedback from Clinical Nurse Specialists. | Personal Non-financial Non-specific | Declare and participate in discussion on all topics as Mabtherea feedback is not being investigated by the guideline. |
| Barbara von Barsewisch | Member of the London Haematological Oncology Nurses Forum | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Marie Waller | Received honoraria from Eusa Pharma for giving a lecture on state of the art management of post-BMT complications, psychological late effects of transplantation. | Personal financial Non specific | Declare and participate in discussion on all topics as state of the art management of post-BMT complications, psychological late effects of transplantation is not being investigated by the guideline. |
| Marie Waller | Received reimbursement of travelling expenses and subsistence from EBMT UK for helping with the administration of an education study day. | Personal financial Non-specific | Declare and participate in discussion on all topics as expenses not beyond a reasonable amount. |
| Marie Waller | Member of the EBMT UK nurses group. | Personal Non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
| Marie Waller | Committee member of the trust board charity. | Personal non-financial Non-specific | Chair persons action to declare and participate in discussions on all topics |
F.3. Expert advisors to the Guideline Committee
| Professor David Barnett | Professor in Diagnostic Haematology & UK NEQAS LI Director, Sheffield Teaching Hospitals NHS Foundation Trust |
| Dr Robert Hills | Reader in Translational Statistics, Head HCTU, Department of Haematology, Cardiff University School of Medicine |
F.4. Individuals carrying our literature reviews and complementary work
| Overall Co-ordinators | |
|---|---|
| Dr John Graham | Director, National Collaborating Centre for Cancer, Cardiff |
| Dr Andrew Champion | Centre Manager, National Collaborating Centre for Cancer, Cardiff |
| Angela Bennett | Assistant Centre Manager, National Collaborating Centre for Cancer, Cardiff |
| Project Managers | |
| Lianne Gwillim | National Collaborating Centre for Cancer, Cardiff |
| Senior Researcher | |
| Dr Nathan Bromham | National Collaborating Centre for Cancer, Cardiff |
| Researchers | |
| Susan O'Connell | National Collaborating Centre for Cancer, Cardiff |
| Information Specialists | |
| Stephanie Arnold | National Collaborating Centre for Cancer, Cardiff |
| Senior Health Economist | |
| Matthew Prettyjohns | National Collaborating Centre for Cancer, Cardiff |
| Health Economist | |
| James Hawkins | National Collaborating Centre for Cancer, Cardiff |
| Needs Assessment | |
| Verity Bellamy | Northern & Yorkshire Knowledge and Intelligence Team, Public Health England |
| Stephen Oliver | Department of Health Sciences, University of York & Hull, York Medical School |
F.5. Organisations invited to comment on the guideline development
| 5 Boroughs Partnership NHS Foundation Trust | National Atrial Fibrillation Clinical Policy Forum |
|---|---|
| Academy for Healthcare Science | National Clinical Guideline Centre |
| Acorns Children's Hospice | National Collaborating Centre for Mental Health |
| Aintree University Hospital NHS Foundation Trust | National Collaborating Centre for Women's and Children's Health |
| Alder Hey Children's NHS Foundation Trust | National Deaf Children's Society |
| Anthony Nolan | National Institute for Health Research |
| Association of Anaesthetists of Great Britain and Ireland | NHS Choices |
| Beckman Coulter | NHS Chorley and South Ribble CCG |
| Belfast Health and Social Care Trust | NHS England |
| Blood & Marrow Transplantation Clinical Reference Group NHS England | NHS Health at Work |
| Boehringer Ingelheim | NHS Somerset CCG |
| Boehringer Ingelheim Ltd | Northern Health and Social Care Trust |
| British HIV Association | Nursing and Midwifery Council |
| British Medical Association | Nutricia Advanced Medical Nutrition |
| British Medical Journal | Public Health England |
| British Nuclear Cardiology Society | Roche Products |
| British Psychological Society | Royal College of Anaesthetists |
| British Red Cross | Royal College of General Practitioners |
| Cambridge University Hospitals NHS Foundation Trust | Royal College of General Practitioners in Wales |
| Cancer Research UK | Royal College of Midwives |
| Caplond Services | Royal College of Nursing |
| Care Quality Commission | Royal College of Obstetricians and Gynaecologists |
| Chartered Society of Physiotherapy | Royal College of Paediatrics and Child Health |
| Children's Cancer and Leukaemia Group | Royal College of Pathologists |
| College of Paramedics | Royal College of Physicians |
| County Durham and Darlington NHS Foundation Trust | Royal College of Psychiatrists |
| CTI Life Sciences | Royal College of Radiologists |
| Department of Health | Royal College of Speech and Language Therapists |
| Department of Health, Social Services and Public Safety - Northern Ireland | Royal College of Surgeons of England |
| East of England Strategic Clinical Network | Royal Pharmaceutical Society |
| Faculty of Dental Surgery | Sandoz Ltd |
| Gilead Sciences Ltd | Scottish Intercollegiate Guidelines Network |
| Gloucestershire Hospitals NHS Foundation Trust | Sebia |
| Greenwich & Bexley Community Hospice | Sheffield Teaching Hospitals NHS Foundation Trust |
| Health and Care Professions Council | Social Care Institute for Excellence |
| Health and Social Care Information Centre | Somerset, Wiltshire, Avon and Gloucestershire Cancer Services Operational Group |
| Healthcare Improvement Scotland | South Eastern Health and Social Care Trust |
| Healthcare Quality Improvement Partnership | South Wales Cancer Network |
| Janssen | Southern Health & Social Care Trust |
| Leukaemia & Lymphoma Research | Teenagers and Young Adults with Cancer |
| Leukaemia CARE | The British Society for Haematology |
| Manchester Cancer | The Intensive Care Society |
| Mastercall Healthcare | The Royal Surrey County Hospital |
| MDS UK Patient Support Group | University Hospital Birmingham NHS Foundation Trust |
| Medicines and Healthcare Products Regulatory Agency | Welsh Government |
| Ministry of Defence | Welsh Scientific Advisory Committee |
| Napp Pharmaceuticals Ltd | Western Health and Social Care Trust |
- People and organisations involved in the production of this guideline - Addendum...People and organisations involved in the production of this guideline - Addendum to Haematological Cancers
- Taxonomy Links for Nucleotide (Select 10436478) (1)Taxonomy
- Full text in PMC (nucleotide) for Gene (Select 28580) (124)PMC
- Taxonomy Links for Protein (Select 30026505) (1)Taxonomy
- Full text in PMC (nucleotide) for Gene (Select 732808) (8)PMC
Your browsing activity is empty.
Activity recording is turned off.
See more...